Sybil Danby

Senior VP of Business Development and Strategy

Sybil Danby, Senior Vice President of Business Development and Strategy. She joined The Center for Breakthrough Medicines with 15 years of industry experience across both technical and commercial roles. Most recently, Sybil was responsible for Business Development at Paragon Bioservices, which was acquired by Catalent Pharma Solutions in 2019 for $1.2 billion. In that role she interfaced with over 40 clients from top-tier gene therapy companies, negotiated large strategic contracts, and more than doubled the business every year for three years straight. Prior to joining Paragon, Sybil was part of the Single Use Technologies Business Unit at Pall, supporting upstream customers to adopt innovative single-use bioreactor technologies for the production of advanced therapies including AAV gene therapies, oncolytic viruses, and cell therapies. Sybil spent nine years at GSK, working in both the manufacturing and R&D organizations supporting the development, technology transfer, and manufacture of multiple clinical and commercial monoclonal antibody products. During her time at GSK, Sybil developed extensive expertise in the area of bioreactor scaling and cell culture process development, contributing to the development and characterization of upstream processes for multiple products. Sybil obtained her B.A. in Biology from the University of Rochester and her M.S. in Biology from West Chester University of Pennsylvania.